OnKure Therapeutics (OKUR) Other Non-Current Liabilities (2021 - 2026)
OnKure Therapeutics' (OKUR) quarterly Other Non-Current Liabilities came in at $12000.0 in Q1 2026, down 70.0% YoY from $40000.0 in Q1 2025, and little changed on a QoQ basis from $12000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 3 years of Other Non-Current Liabilities data on file, last reported at $12000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 70.0% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12000.0 (down 70.0% YoY) and the FY2025 annual result came in at $12000.0, changed N/A from the prior year.
- Other Non-Current Liabilities was little changed at $12000.0 in Q1 2026, from $12000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $40000.0 in Q1 2025 to a low of $12000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2021 | 167,000.00 |